Replies to post #188263 on Biotech Values

[DewDiligence]

Animal models of NASH:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353364/

[DewDiligence]

ENTA—an interesting development would be a cylophilin inhibitor for liver fibrosis that could potentially be used with an FXR—that would give them a real edge.

ICPT certainly doesn’t have a cyclophilin inhibitor and I highly doubt that GILD does, so such a combination would indeed be unique. Whether it would be safe and effective is another matter, of course.